论文部分内容阅读
目的观察黄芪、丹参加常规护肝药治疗血吸虫病肝纤维化的效果。方法随机将血吸虫肝纤维化患者分为治疗组和对照组,两组均给予血吸虫病原治疗后,对照组使用常规护肝药治疗,治疗组在此基础上加用黄芪、丹参注射液。疗程结束后通过血清纤维化指标及B超检查,比较两组的治疗效果。结果治疗组血清透明质酸、Ⅲ型前胶原、Ⅳ型胶原、层黏连蛋白水平较治疗前均显著下降,而对照组治疗前后变化不显著。治疗组肝回缩率及肝实质改善率分别为74.1%和32.4%,对照组为23.7%和6.8%,两组差异有统计学意义(P均(0.05)。结论黄芪、丹参加常规护肝药治疗血吸虫病肝纤维化,效果优于单纯使用常规护肝药治疗,有较高的临床应用价值。
Objective To observe the effect of Radix Astragali and Radix Salviae Miltiorrhizae on the treatment of liver fibrosis caused by schistosomiasis with routine hepatoprotective drugs. Methods The patients with schistosomiasis hepatic fibrosis were randomly divided into treatment group and control group. Both groups were given schistosomiasis treatment, while those in control group were treated with conventional hepatoprotective drugs. The treatment group was treated with astragalus membranaceus and Salvia miltiorrhiza. After the end of treatment by serum fibrosis indicators and B-ultrasound, the treatment effect of the two groups were compared. Results The levels of serum hyaluronic acid, type Ⅲ procollagen, type Ⅳ collagen and laminin in treatment group were significantly lower than those before treatment, while those in control group did not change significantly before and after treatment. The improvement rate of liver shrinkage and liver parenchyma in the treatment group were 74.1% and 32.4%, respectively, and 23.7% and 6.8% in the control group, respectively (all P <0.05) .Conclusion Astragalus, Drug treatment of schistosomiasis liver fibrosis, the effect is better than the simple use of conventional hepatoprotective therapy, a higher clinical value.